ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Lung Cancer

MBCC 2016 hero

Lung Cancer

The term “HER2-positive lung cancer” may actually refer to two distinct entities, according to a new study. HER2 mutations and HER2 amplifications were found in similar numbers of lung adenocarcinoma cases, but they did not occur in the same samples, suggesting HER2-targeted agents should differentiate between mutation and amplification.

The use of low molecular-weight heparin failed to improve either metastasis-free or overall survival in newly diagnosed lung cancer patients.

Patients diagnosed with non-small-cell lung cancer (NSCLC) at a younger age are far more likely to harbor a targetable genomic alteration than older patients.

This review outlines the diagnostic and therapeutic challenges associated with the increased number of screen-identified indeterminate lung nodules, highlighting currently recommended follow-up and management algorithms, as well as the various methods of nodule localization, tissue diagnosis, and definitive local therapeutic modalities.

Radiologic screening for lung cancer had a long and unsuccessful history until the advent of low-dose computed tomography (CT) screening and the completion of the National Lung Screening Trial, which demonstrated an improvement in lung cancer–specific mortality in a high-risk population.

On December 11, 2015, the US Food and Drug Administration (FDA) approved alectinib for patients with ALK-rearrangement positive non-small cell lung cancer (NSCLC) that is refractory to another ALK-targeted oral drug, crizotinib.

A study showed that the use of intraoperative frozen section diagnosis correlated strongly with final pathology for peripheral small-sized lung adenocarcinoma.

Pages

Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.